Scribe Therapeutics prepares for IPO
Gene editing company Scribe Therapeutics has filed for an initial public offering (IPO), becoming the latest biotech to test improving capital market conditions. The company is developing next generation CRISPR technologies designed to improve the precision and safety of gene editing.
The IPO comes as investor confidence is returning to the biotech sector after several challenging years. Scribe intends to use the proceeds to advance its pipeline, including in vivo genetic medicines targeting cardiovascular disease through lipid-lowering therapies.
Scribe’s IPO filing suggests financing conditions may be improving for innovative biotech companies. Public market access is vital for advancing capital-intensive CGT programmes, and continued IPO activity could point to renewed investor confidence across the advanced therapies sector.
Read more via Pharma Phorum
Coregen receives FDA clearance for CRISPR-engineered solid tumour cell therapy
Coregen has received FDA Investigational New Drug (IND) clearance to begin a Phase 1/2a trial of CRG-150, a CRISPR-engineered regulatory T cell therapy for multiple solid tumour types. Compared with conventional Treg therapies, CRG-150 has been engineered to enhance tumour infiltration while limiting immune suppression in healthy tissue. The trial will evaluate the therapy across several advanced solid tumours.
Solid tumours remain one of the most challenging areas in cell therapy. FDA clearance for approaches such as CRG-150 highlights continued progress in extending engineered cell therapies into indications where clinical success has historically been difficult.
Read more via Inside Precision Medicine
Prime Medicine wins patent dispute against Beam Therapeutics
Prime Medicine has announced a positive resolution to its arbitration with Beam Therapeutics over intellectual property rights relating to gene editing technology. A tribunal found that prime did not breach its 2019 collaboration agreement with Beam by developing PM647, a prime-editing candidate for alpha-1 antitrypsin deficiency (AATD). Prime owes Beam no damages and can now advance PM647 into the clinic. Both companies originated from research in David Liu’s lab at Harvard and both assets aim to correct the same mutation in SERPINA1.
The decision confirms that Prime can continue developing its lead programme which will directly compete with Beam in AATD. This serves as a reminder that as gene editing modalities mature, IP and collaboration-agreement disputes between companies with shared academic origins are likely to keep surfacing and outcomes like this one will shape how freely competitors can pursue overlapping genetic targets.
Read more via Globe Newswire
A strong week for Fate Therapeutics’ off-the-shelf CAR-T platform
Fate Therapeutics announced positive early clinical data for FT819, an off-the-shelf iPSC-derived CAR-T therapy in treatment-resistant autoimmune disease.
Early results demonstrated encouraging clinical activity alongside a favourable safety profile, adding to growing evidence that allogeneic CAR-T therapies may have a role beyond oncology. The company also received FDA clearance of its IND application for FT839, enabling clinical evaluation of another next-generation off-the shelf cell therapy candidate.
Together, the updates strengthen the case for iPSC-derived off-the-shelf CAR-T therapies as a viable alternative to autologous approaches in autoimmune disease. As interest in this field grows, further positive data will be closely watched to confirm their therapeutic potential.
Read more via Fierce Biotech and Globe Newswire
)